Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RAF1 | P04049 | 3/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011650 | 0.88 | CNR2 (0.50) | MAPK14CNR1CNR2ALDH1A1MEN1 | |
| SCHEMBL1011942 | 0.85 | CNR2 (0.47) | MAPK14CNR1CNR2ALDH1A1MEN1 | |
| SCHEMBL24096657 | 0.83 | ALDH1A1 (0.39) | MAPK14ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL1013171 | 0.82 | ALDH1A1 (0.56) | MAPK14CNR2ALDH1A1MEN1KMT2A | |
| SCHEMBL1012827 | 0.81 | MAPK14 (0.45) | MAPK14ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL25793255 | 0.81 | ALDH1A1 (0.45) | MAPK14CNR1CNR2ALDH1A1RAF1 | |
| SCHEMBL1012497 | 0.80 | RAF1 (0.45) | MAPK14ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL30311273 | 0.80 | ALDH1A1 (0.44) | MAPK14CNR1CNR2ALDH1A1RAF1 | |
| SCHEMBL1013308 | 0.80 | RAF1 (0.47) | MAPK14ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL23966924 | 0.78 | BRAF (0.47) | MAPK14ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091413-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2024-09-17 | — | — | US | disclosed |
| EP-4146348-B1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-4146348-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20220064173-A1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2022-03-03 | — | — | US | disclosed |
| WO-2021242505-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-02 | — | — | WO | disclosed |
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-11161852-B1 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | MAPK14 454/4885CNR1 2194/4885CNR2 3084/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | MAPK14 454/4885CNR1 2194/4885CNR2 3084/4885 |
| US-12091413-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | MAPK14 454/4885CNR1 2194/4885CNR2 3084/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | MAPK14 717/4885CNR1 4436/4885CNR2 4544/4885 |
| US-11161852-B1 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | MAPK14 454/4885CNR1 2194/4885CNR2 3084/4885 |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | MAPK14 454/4885CNR1 2194/4885CNR2 3084/4885 |
| US-20220064173-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | MAPK14 454/4885CNR1 2194/4885CNR2 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.